Sign in
Active, not recruitingNo phase

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

Key facts

Who runs it
Pentax Medical
Where
Baltimore, Chapel Hill, Chicago, Cleveland, Danville, Manhasset, New York, Orange, Philadelphia, Rochester, and Sarasota, United StatesSee the 11 sites
Trial code
Status
Active, not recruiting
People taking part
150 people, planned
Started
Mar 2016
Ended
Dec 2025
Type of study
Interventional
Treatments tested
  • CryoBalloon Ablation System
Record updated
13 January 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Low- or high-grade non-nodular, previously untreated ("treatment naïve") dysplastic BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer (ImCA) is identified during patient screening, this may be treated with Endoscopic Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion
  • BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1
  • Older than 18 years of age at time of consent
  • Operable per institution's standards
  • Provides written informed consent on the approved informed consent form
  • Willing and able to comply with study requirements for follow-up

Who cannot take part

  • Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope (patients may have the stenosis/stricture dilated and then be treated with CryoBalloon ablation under this protocol at a subsequent procedure ≥2 weeks later)
  • Any endoscopically-visualized abnormalities such as ulcers, masses or nodules. Neoplastic nodules must first be treated with EMR ≥6 weeks prior to planned treatment under this protocol
  • Prior distal esophagectomy
  • History of esophageal cancer more extensive than T1a or not meeting criteria for low risk of recurrence (confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion)
  • History of esophageal varices
  • Any clinical or histological suspicion of esophageal adenocarcinoma invading into the submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with positive deep margin by EMR
  • Life expectancy ≤3 years, as judged by the site investigator
  • Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological analysis
  • Symptomatic untreated strictures
  • Large (>4cm) hiatal hernia
  • Active esophagitis grade B or higher
  • Severe medical comorbidities precluding endoscopy
  • Uncontrolled coagulopathy
  • Pregnant or planning to become pregnant during period of study participation
  • Patient refuses or is unable to provide written informed consent
  • General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation

Where in United States

  • John HopkinsBaltimore, United States
  • University of North Carolina School of MedicineChapel Hill, United States
  • University of ChicagoChicago, United States
  • University Hospitals Cleveland Medical Center*Cleveland, United States
  • Geisinger Medical CenterDanville, United States
  • Northwell HealthManhasset, United States
  • New York Presbyterian Hospital-Columbia University Medical CenterNew York, United States
  • UC IrvineOrange, United States
  • Thomas Jefferson UniversityPhiladelphia, United States
  • Mayo ClinicRochester, United States
  • Sarasota Memorial HospitalSarasota, United States

About the trial

What the trial wants to find out

To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

The group in the trial

  • CryoBalloon Ablation SystemOther group

    Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium
Publications
Record updated
13 January 2025